TY - JOUR AU - Melero, I. AU - Hervas-Stubbs, S. AU - Glenne, M. AU - Pardoll, D. M. AU - Chen, L. PY - 2007 DA - 2007// TI - Immunostimulatory monoclonal antibodies for cancer therapy JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2051 DO - 10.1038/nrc2051 ID - Melero2007 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Robert, C. AU - Thomas, L. AU - Bondarenko, I. AU - O’Day, S. AU - Weber, J. PY - 2011 DA - 2011// TI - Ipilimumab plus dacarbazine for previously untreated metastatic melanoma JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1104621 DO - 10.1056/NEJMoa1104621 ID - Robert2011 ER - TY - BOOK AU - Friedman, L. AU - Furberg, C. AU - DeMets, D. PY - 1998 DA - 1998// TI - Fundamentals of Clinical Trials, 3rd Ed PB - Springer-Verlag New York Inc. CY - New York UR - https://doi.org/10.1007/978-1-4757-2915-3 DO - 10.1007/978-1-4757-2915-3 ID - Friedman1998 ER - TY - JOUR AU - Wolchok, J. D. AU - Neyns, B. AU - Linette, G. AU - Negrier, S. AU - Lutzky, J. PY - 2010 DA - 2010// TI - Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70334-1 DO - 10.1016/S1470-2045(09)70334-1 ID - Wolchok2010 ER - TY - JOUR AU - Sosman, J. A. AU - Unger, J. M. AU - Liu, P. Y. AU - Flaherty, L. E. AU - Park, M. S. PY - 2002 DA - 2002// TI - Adjuvant immunotherapy of resected, intermediate thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of, HLA class I antigen expression on outcome JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.08.072 DO - 10.1200/JCO.2002.08.072 ID - Sosman2002 ER - TY - JOUR AU - Small, E. J. AU - Schellhammer, P. F. AU - Higano, C. S. PY - 2006 DA - 2006// TI - Placebo-controlled phase, III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.5252 DO - 10.1200/JCO.2005.04.5252 ID - Small2006 ER - TY - JOUR AU - Fine, G. D. PY - 2007 DA - 2007// TI - Consequences of delayed treatment effects on analysis of time-to-event endpoints JO - Drug Inf J VL - 41 ID - Fine2007 ER - TY - JOUR AU - Schwartzentruber, D. J. AU - Lawson, D. H. AU - Richards, J. M. AU - Conry, R. M. AU - Miller, D. M. PY - 2011 DA - 2011// TI - gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1012863 DO - 10.1056/NEJMoa1012863 ID - Schwartzentruber2011 ER - TY - JOUR AU - Kirkwood, J. M. AU - Strawderman, M. H. AU - Ernstoff, M. S. AU - Smith, T. J. AU - Borden, E. C. AU - Blum, R. H. PY - 1996 DA - 1996// TI - Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 JO - J Clin Oncol VL - 14 ID - Kirkwood1996 ER - TY - JOUR AU - Kirkwood, J. M. AU - Ibrahim, J. G. AU - Sondak, V. K. AU - Richards, J. AU - Flaherty, L. E. AU - Ernstoff, M. S. PY - 2000 DA - 2000// TI - High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial, E1690/S9111/C9190 JO - J Clin Oncol VL - 18 ID - Kirkwood2000 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Suciu, S. AU - Testori, A. AU - Santinami, M. AU - Kruit, W. H. J. PY - 2012 DA - 2012// TI - Long-term results of the randomized phase, III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.41.3799 DO - 10.1200/JCO.2011.41.3799 ID - Eggermont2012 ER - TY - JOUR AU - Psyrri, A. AU - Kwong, M. AU - DiStasio, S. AU - Lekakis, L. AU - Kassar, M. PY - 2004 DA - 2004// TI - Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.01.108 DO - 10.1200/JCO.2004.01.108 ID - Psyrri2004 ER - TY - JOUR AU - Kantarjian, H. AU - O’Brien, S. AU - Garcia-Manero, G. AU - Faderl, S. AU - Ranvandi, F. PY - 2012 DA - 2012// TI - Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy JO - Cancer VL - 118 UR - https://doi.org/10.1002/cncr.26568 DO - 10.1002/cncr.26568 ID - Kantarjian2012 ER - TY - JOUR AU - Rea, D. AU - Vellenga, E. AU - Junghanß, C. AU - Baccarani, M. AU - Kantargian, H. PY - 2012 DA - 2012// TI - Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib [0199] JO - Haematologica VL - 97 ID - Rea2012 ER - TY - JOUR AU - Maio, M. AU - Bondarenko, I. AU - Robert, C. AU - Thomas, L. AU - Garbe, C. PY - 2012 DA - 2012// TI - Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) + dacarbazine (DTIC) on phase 3 study, CA184-024 [1127P] JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds257 DO - 10.1093/annonc/mds257 ID - Maio2012 ER - TY - JOUR AU - Lebbe, C. AU - Weber, J. S. AU - Maio, M. AU - Neyns, B. AU - Harmankaya, K. PY - 2012 DA - 2012// TI - Five-year survival rates for patients (Pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase, II trials [1116PD] JO - Ann Oncol VL - 23 ID - Lebbe2012 ER - TY - JOUR AU - Ribas, A. AU - Kefford, R. AU - Marshall, M. A. AU - Punt, C. J. A. AU - Haanen, J. B. PY - 2013 DA - 2013// TI - Phase, III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.6112 DO - 10.1200/JCO.2012.44.6112 ID - Ribas2013 ER - TY - JOUR AU - O’Brien, P. C. AU - Fleming, T. R. PY - 1979 DA - 1979// TI - A multiple testing procedure for clinical trials JO - Biometrics VL - 35 UR - https://doi.org/10.2307/2530245 DO - 10.2307/2530245 ID - O’Brien1979 ER - TY - JOUR AU - Pocock, S. J. PY - 1977 DA - 1977// TI - Group sequential methods in the design and analysis of clinical trials JO - Biometrika VL - 64 UR - https://doi.org/10.1093/biomet/64.2.191 DO - 10.1093/biomet/64.2.191 ID - Pocock1977 ER - TY - JOUR AU - Lan, K. AU - DeMets, D. PY - 1983 DA - 1983// TI - Discrete sequential boundaries for clinical trials JO - Biometrika VL - 70 UR - https://doi.org/10.2307/2336502 DO - 10.2307/2336502 ID - Lan1983 ER - TY - JOUR AU - Pampallona, S. AU - Tsiatis, A. AU - Kim, K. M. PY - 2001 DA - 2001// TI - Interim monitoring of group sequential trials using spending functions for the type I and II error probabilities JO - Drug Inf J VL - 35 UR - https://doi.org/10.1177/009286150103500408 DO - 10.1177/009286150103500408 ID - Pampallona2001 ER - TY - BOOK PY - 1979 DA - 1979// TI - WHO Handbook for Reporting Results of Cancer Treatment PB - Springer-Verlag New York Inc. CY - Geneva ID - ref23 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. AU - Wanders, J. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid tumors JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.3.205 DO - 10.1093/jnci/92.3.205 ID - Therasse2000 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumors: revised, RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Weber, J. AU - Thompson, J. A. AU - Hamid, O. AU - Minor, D. AU - Amin, A. PY - 2009 DA - 2009// TI - A randomized, double-blind, placebo-controlled, phase, II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1024 DO - 10.1158/1078-0432.CCR-09-1024 ID - Weber2009 ER - TY - JOUR AU - O’Day, S. J. AU - Maio, M. AU - Chiarion-Sileni, V. AU - Gajewski, T. F. AU - Pehamberger, H. PY - 2010 DA - 2010// TI - Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase, II study JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdq013 DO - 10.1093/annonc/mdq013 ID - O’Day2010 ER - TY - JOUR AU - Margolin, K. AU - Ernstoff, M. S. AU - Hamid, O. AU - Lawrence, D. AU - McDermott, D. PY - 2012 DA - 2012// TI - Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(12)70090-6 DO - 10.1016/S1470-2045(12)70090-6 ID - Margolin2012 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O’Day, S. AU - Weber, J. S. AU - Hamid, O. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER - TY - STD TI - The Yervoy (Ipilimumab) Summary of Product Characteristics.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf, UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf ID - ref30 ER - TY - STD TI - The Yervoy (Ipilimumab) US Package Insert.http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s044lbl.pdf, UR - http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s044lbl.pdf ID - ref31 ER - TY - JOUR AU - Kuk, A. Y. C. AU - Chen, C. H. PY - 1992 DA - 1992// TI - A mixture model combining logistic regression with proportional hazards regression JO - Biometrika VL - 79 UR - https://doi.org/10.1093/biomet/79.3.531 DO - 10.1093/biomet/79.3.531 ID - Kuk1992 ER - TY - JOUR AU - Sy, J. P. AU - Taylor, J. M. G. PY - 2000 DA - 2000// TI - Estimation in a cox proportional hazards cure model JO - Biometrics VL - 56 UR - https://doi.org/10.1111/j.0006-341X.2000.00227.x DO - 10.1111/j.0006-341X.2000.00227.x ID - Sy2000 ER - TY - JOUR AU - Peng, Y. AU - Dear, K. B. G. PY - 2000 DA - 2000// TI - A nonparametric mixture model for cure rate estimation JO - Biometrics VL - 56 UR - https://doi.org/10.1111/j.0006-341X.2000.00237.x DO - 10.1111/j.0006-341X.2000.00237.x ID - Peng2000 ER - TY - JOUR AU - Farewell, V. T. PY - 1982 DA - 1982// TI - The use of mixture models for the analysis of survival data with long-term survivors JO - Biometrics VL - 38 UR - https://doi.org/10.2307/2529885 DO - 10.2307/2529885 ID - Farewell1982 ER - TY - JOUR AU - Harrington, D. P. AU - Fleming, T. R. PY - 1982 DA - 1982// TI - A class of rank test procedures for censored survival data JO - Biometrika VL - 69 UR - https://doi.org/10.1093/biomet/69.3.553 DO - 10.1093/biomet/69.3.553 ID - Harrington1982 ER - TY - BOOK AU - Fleming, T. R. AU - Harrington, D. P. PY - 1991 DA - 1991// TI - Counting Processes and Survival Analysis PB - John Wiley CY - New York ID - Fleming1991 ER -